A novel DEX vaccine containing antigens and matured with either the TLR-3 (toll-like receptor-3) ligand-induced robust activation of melanoma-specific CD8+ T cells, as well as the selection of cytotoxic CD8+ T cells, NK, and NK-T cells to the tumor site, resulting in noticeably decreased tumor growth and improved survival rates [279]. The gene discussed is CD8A; the disease is melanoma.